Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
Aspire Biopharma Holdings (NASDAQ:ASBP) has initiated production of its single-dose pre-workout supplement utilizing its patent-pending sublingual delivery technology. The supplement, featuring 100mg of caffeine and beta alanine, will be packaged in convenient single-serving sachets that don't require water mixing.
The company plans to conduct consumer and safety testing in Q2 2025, with the product expected to launch in specialty nutritional retailers in 2025. Desert Stream Inc., a leading private label manufacturer, is handling the initial production. The supplement will be available in at least three flavors.
The product enters a growing market, with global pre-workout supplements valued at USD 19.90 billion in 2023 and projected to reach USD 29.77 billion by 2032, growing at a 4.58% CAGR. The market growth is driven by increasing fitness awareness, rising demand for performance-enhancing nutritional products, and growing fitness center numbers.
Aspire Biopharma Holdings (NASDAQ:ASBP) ha avviato la produzione del suo integratore pre-allenamento monodose utilizzando la sua tecnologia di somministrazione sublinguale in attesa di brevetto. L'integratore, che contiene 100 mg di caffeina e beta alanina, sarà confezionato in pratiche bustine monodose che non richiedono acqua per essere miscelate.
L'azienda prevede di condurre test di consumo e di sicurezza nel secondo trimestre del 2025, con il prodotto che dovrebbe essere lanciato nei negozi di nutrizione specializzati nel 2025. Desert Stream Inc., un importante produttore di marchi privati, gestirà la produzione iniziale. L'integratore sarà disponibile in almeno tre gusti.
Il prodotto entra in un mercato in crescita, con gli integratori pre-allenamento globali valutati 19,90 miliardi di USD nel 2023 e si prevede che raggiungano 29,77 miliardi di USD entro il 2032, crescendo a un CAGR del 4,58%. La crescita del mercato è guidata da una crescente consapevolezza del fitness, dalla domanda in aumento di prodotti nutrizionali che migliorano le prestazioni e dall'aumento del numero di centri fitness.
Aspire Biopharma Holdings (NASDAQ:ASBP) ha iniciado la producción de su suplemento pre-entrenamiento de dosis única utilizando su tecnología de entrega sublingual pendiente de patente. El suplemento, que contiene 100 mg de cafeína y beta alanina, será empaquetado en prácticos sobres de una sola porción que no requieren mezcla con agua.
La empresa planea realizar pruebas de consumo y de seguridad en el segundo trimestre de 2025, con el producto que se espera que se lance en minoristas de nutrición especializada en 2025. Desert Stream Inc., un importante fabricante de marcas privadas, se encargará de la producción inicial. El suplemento estará disponible en al menos tres sabores.
El producto entra en un mercado en crecimiento, con los suplementos pre-entrenamiento globales valorados en 19.90 mil millones de USD en 2023 y se proyecta que alcancen 29.77 mil millones de USD para 2032, creciendo a una CAGR del 4.58%. El crecimiento del mercado está impulsado por una creciente conciencia sobre el fitness, una demanda en aumento de productos nutricionales que mejoran el rendimiento y un aumento en el número de centros de fitness.
Aspire Biopharma Holdings (NASDAQ:ASBP)는 특허 출원 중인 설하 전달 기술을 활용하여 단일 복용량의 운동 전 보충제 생산을 시작했습니다. 100mg의 카페인과 베타 알라닌이 포함된 이 보충제는 물 혼합이 필요 없는 편리한 단일 포장으로 제공됩니다.
회사는 2025년 2분기에 소비자 및 안전 테스트를 실시할 계획이며, 이 제품은 2025년에 전문 영양 소매점에서 출시될 것으로 예상됩니다. 주요 개인 상표 제조업체인 Desert Stream Inc.가 초기 생산을 담당합니다. 이 보충제는 최소 세 가지 맛으로 제공될 예정입니다.
이 제품은 성장하는 시장에 진입하며, 2023년 전 세계 운동 전 보충제 시장은 199억 달러로 평가되며, 2032년까지 297억 7천만 달러에 이를 것으로 예상되며, 연평균 성장률(CAGR)은 4.58%입니다. 시장 성장의 원인은 피트니스에 대한 인식 증가, 성능 향상 영양 제품에 대한 수요 증가, 그리고 피트니스 센터 수의 증가입니다.
Aspire Biopharma Holdings (NASDAQ:ASBP) a lancé la production de son complément pré-entraînement à dose unique en utilisant sa technologie de livraison sublinguale en instance de brevet. Le complément, contenant 100 mg de caféine et de bêta-alanine, sera conditionné dans des sachets pratiques à dose unique qui ne nécessitent pas de mélange avec de l'eau.
L'entreprise prévoit de réaliser des tests consommateurs et de sécurité au deuxième trimestre 2025, avec un lancement prévu dans des magasins spécialisés en nutrition en 2025. Desert Stream Inc., un fabricant leader de marques privées, se chargera de la production initiale. Le complément sera disponible en au moins trois saveurs.
Le produit entre sur un marché en pleine croissance, avec des compléments pré-entraînement mondiaux évalués à 19,90 milliards USD en 2023 et projetés pour atteindre 29,77 milliards USD d'ici 2032, avec un taux de croissance annuel composé (CAGR) de 4,58%. La croissance du marché est alimentée par une prise de conscience croissante du fitness, une demande accrue pour des produits nutritionnels améliorant les performances et une augmentation du nombre de centres de fitness.
Aspire Biopharma Holdings (NASDAQ:ASBP) hat die Produktion seines Einzeldosis-Pre-Workout-Nahrungsergänzungsmittels mit seiner patentierten sublingualen Abgabetechnologie initiiert. Das Nahrungsergänzungsmittel, das 100 mg Koffein und Beta-Alanin enthält, wird in praktischen Einzeldosisbeuteln verpackt, die kein Wasser zum Mischen benötigen.
Das Unternehmen plant, im 2. Quartal 2025 Verbrauchertests und Sicherheitstests durchzuführen, wobei das Produkt voraussichtlich 2025 in spezialisierten Einzelhändlern für Nahrungsergänzungsmittel auf den Markt kommen wird. Desert Stream Inc., ein führender Hersteller von Eigenmarken, übernimmt die anfängliche Produktion. Das Nahrungsergänzungsmittel wird in mindestens drei Geschmacksrichtungen erhältlich sein.
Das Produkt betritt einen wachsenden Markt, wobei der globale Markt für Pre-Workout-Nahrungsergänzungsmittel im Jahr 2023 auf 19,90 Milliarden USD geschätzt wird und bis 2032 auf 29,77 Milliarden USD anwachsen soll, mit einer jährlichen Wachstumsrate (CAGR) von 4,58%. Das Marktwachstum wird durch das steigende Fitnessbewusstsein, die wachsende Nachfrage nach leistungssteigernden Ernährungsprodukten und die zunehmende Anzahl von Fitnessstudios angetrieben.
- Entry into large and growing pre-workout supplement market valued at $19.90B
- Partnership with established manufacturer Desert Stream Inc.
- Innovative product featuring patent-pending sublingual delivery technology
- Convenient single-serving format addressing user pain points
- Product still in early production phase with testing not yet commenced
- Market entry not expected until 2025, indicating no immediate revenue impact
- Faces competition in crowded pre-workout supplement market
Insights
Aspire Biopharma's commencement of pre-workout supplement production represents a tangible step toward commercialization of their patent-pending sublingual delivery technology. While still in early stages with consumer testing planned for Q2 2025, this development signals the company's first potential revenue-generating product application.
The market opportunity appears substantial, with cited research showing the global pre-workout supplement market valued at
Aspire's product differentiation centers on convenient single-dose packaging and their proprietary sublingual delivery method, eliminating the need for mixing powders. This approach could appeal to on-the-go consumers seeking precise dosing and convenience, potentially commanding premium pricing if efficacy is demonstrated.
For a micro-cap company (
Investors should note that significant milestones remain before commercialization, including successful consumer testing, regulatory compliance, and establishing distribution channels. The timeline for meaningful revenue contribution remains uncertain beyond the broad "2025" launch target.
Plans to conduct consumer and safety testing during second quarter 2025
Desert Stream Inc.,a leading private label manufacturer in the health and wellness industry, performing initial production
Single dose pre-workout supplement expected to be available in at least three flavors and launch in specialty retailers of nutritional products in 2025
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / April 11, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending disruptive drug and supplement delivery technology, announced today it has begun initial production of its single dose pre workout supplement utilizing Aspire's patent-pending and proprietary sublingual delivery technology. The clinically dosed pre-workout formula is expected to be conveniently packaged in a single serving sachet for easy on-the-go use. The Company expects to begin consumer and safety testing of this supplement product during the second quarter of 2025.
Aspire's initial pre-workout supplement features 100mg of caffeine as well as beta alanine (which helps reduce lactic acid buildup) and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts maximize their performance potential. Aspire's sachets are easy to use, do not need to be mixed with water (no more scoops and messy bottles), and contain a precise amount of caffeine.
Market Overview
With the increasing popularity of fitness and exercise, the demand for pre-workout supplements has grown exponentially. According to Straits Research, "The global pre-workout supplements market was valued at USD 19.90 billion in 2023. It is estimated to reach USD 29.77 billion by 2032, growing at a CAGR of
"We are committed to delivering a platform of the most effective pre-workout formulations in the market, helping athletes of all levels achieve their fitness goals, while staying true to our commitment of providing premium and trusted clinically studied ingredients," said Kraig Higginson, Chief Executive Officer of Aspire. "Aspire has developed a pre-workout product that uses our sublingual delivery method which is expected to allow users to better control the amount of caffeine they need and when it will be delivered in their bodies."
Higginson added, "The team at Desert Stream, known throughout the industry for maintaining the highest of quality product controls, has been very supportive as we plan for future scalability and market penetration."
About Desert Stream, Inc.
Desert Stream Incorporated, based in Nephi, Utah, is a leading Vitamin Supplement Manufacturer with expertise in encapsulation, powder processing, and flexible packaging services.
Specializing in high-quality production methods, Desert Stream Incorporated is dedicated to providing top-notch services to meet the needs of their clients in the health and wellness industry. For more information, please visit https://www.dsiutah.co/
About Aspire Biopharma, Inc.
Headquartered in Humacao, Puerto Rico, Aspire Biopharma has developed a disruptive technology through a novel soluble formulation which addresses emergencies, drug efficacy, dosage management, and response time. For more information, please visit www.aspirebiolabs.com.
Safe Harbor Statement
Certain statements made in this communication are "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as "estimate," "projects," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "would," "should," "future," "propose," "potential," "target," "goal," "objective," "outlook" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Aspire Biopharma Holdings, Inc.
Contact
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Aspire Biopharma (ASBP) launch its pre-workout supplement?
What are the key features of ASBP's new pre-workout supplement?
What is the market size for pre-workout supplements that ASBP is entering?
Which manufacturer is producing ASBP's pre-workout supplement?
